Literature DB >> 28373182

Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice.

Emily L Rossi1,2, Sarah M Dunlap3, Laura W Bowers1,2, Subreen A Khatib1, Steven S Doerstling1, Laura A Smith1, Nikki A Ford3, Darcy Holley2,4, Powel H Brown5,6, Marcos R Estecio7, Donna F Kusewitt7, Linda A deGraffenried3, Scott J Bultman2,4, Stephen D Hursting8,2.   

Abstract

The association between obesity and breast cancer risk and prognosis is well established in estrogen receptor (ER)-positive disease but less clear in HER2-positive disease. Here, we report preclinical evidence suggesting weight maintenance through calorie restriction (CR) may limit risk of HER2-positive breast cancer. In female MMTV-HER2/neu transgenic mice, we found that ERα and ERβ expression, mammary tumorigenesis, and survival are energy balance dependent in association with epigenetic reprogramming. Mice were randomized to receive a CR, overweight-inducing, or diet-induced obesity regimen (n = 27/group). Subsets of mice (n = 4/group/time point) were euthanized after 1, 3, and 5 months to characterize diet-dependent metabolic, transcriptional, and epigenetic perturbations. Remaining mice were followed up to 22 months. Relative to the overweight and diet-induced obesity regimens, CR decreased body weight, adiposity, and serum metabolic hormones as expected and also elicited an increase in mammary ERα and ERβ expression. Increased DNA methylation accompanied this pattern, particularly at CpG dinucleotides located within binding or flanking regions for the transcriptional regulator CCCTC-binding factor of ESR1 and ESR2, consistent with sustained transcriptional activation of ERα and ERβ. Mammary expression of the DNA methylation enzyme DNMT1 was stable in CR mice but increased over time in overweight and diet-induced obesity mice, suggesting CR obviates epigenetic alterations concurrent with chronic excess energy intake. In the survival study, CR elicited a significant suppression in spontaneous mammary tumorigenesis. Overall, our findings suggest a mechanistic rationale to prevent or reverse excess body weight as a strategy to reduce HER2-positive breast cancer risk. Cancer Res; 77(9); 2500-11. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28373182      PMCID: PMC5964334          DOI: 10.1158/0008-5472.CAN-16-2795

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

2.  Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer.

Authors:  Chun-Te Chen; Yi Du; Hirohito Yamaguchi; Jung-Mao Hsu; Hsu-Ping Kuo; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

3.  The ERalpha/ERbeta ratio determines oxidative stress in breast cancer cell lines in response to 17beta-estradiol.

Authors:  Mercedes Nadal-Serrano; Jorge Sastre-Serra; Daniel Gabriel Pons; Antonia María Miró; Jordi Oliver; Pilar Roca
Journal:  J Cell Biochem       Date:  2012-10       Impact factor: 4.429

4.  DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.

Authors:  Kathrin Mutze; Rupert Langer; Felix Schumacher; Karen Becker; Katja Ott; Alexander Novotny; Alexander Hapfelmeier; Heinz Höfler; Gisela Keller
Journal:  Eur J Cancer       Date:  2011-03-31       Impact factor: 9.162

5.  Weight loss after gastric bypass surgery in human obesity remodels promoter methylation.

Authors:  Romain Barres; Henriette Kirchner; Morten Rasmussen; Jie Yan; Francisc R Kantor; Anna Krook; Erik Näslund; Juleen R Zierath
Journal:  Cell Rep       Date:  2013-04-11       Impact factor: 9.423

6.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Authors:  Naoko Honma; Rie Horii; Takuji Iwase; Shigehira Saji; Mamoun Younes; Kaiyo Takubo; Masaaki Matsuura; Yoshinori Ito; Futoshi Akiyama; Goi Sakamoto
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  Developmentally programmed 3' CpG island methylation confers tissue- and cell-type-specific transcriptional activation.

Authors:  Da-Hai Yu; Carol Ware; Robert A Waterland; Jiexin Zhang; Miao-Hsueh Chen; Manasi Gadkari; Govindarajan Kunde-Ramamoorthy; Lagina M Nosavanh; Lanlan Shen
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

8.  Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women.

Authors:  Carol J Fabian; Bruce F Kimler; Joseph E Donnelly; Debra K Sullivan; Jennifer R Klemp; Brian K Petroff; Teresa A Phillips; Trina Metheny; Sonya Aversman; Hung-Wen Yeh; Carola M Zalles; Gordon B Mills; Stephen D Hursting
Journal:  Breast Cancer Res Treat       Date:  2013-10-19       Impact factor: 4.872

9.  Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.

Authors:  Hisani N Horne; Mark E Sherman; Ruth M Pfeiffer; Jonine D Figueroa; Zeina G Khodr; Roni T Falk; Michael Pollak; Deesha A Patel; Maya M Palakal; Laura Linville; Daphne Papathomas; Berta Geller; Pamela M Vacek; Donald L Weaver; Rachael Chicoine; John Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Serghei Malkov; Sally Herschorn; Stephen M Hewitt; Louise A Brinton; Gretchen L Gierach
Journal:  Breast Cancer Res       Date:  2016-02-18       Impact factor: 6.466

10.  Ensembl 2016.

Authors:  Andrew Yates; Wasiu Akanni; M Ridwan Amode; Daniel Barrell; Konstantinos Billis; Denise Carvalho-Silva; Carla Cummins; Peter Clapham; Stephen Fitzgerald; Laurent Gil; Carlos García Girón; Leo Gordon; Thibaut Hourlier; Sarah E Hunt; Sophie H Janacek; Nathan Johnson; Thomas Juettemann; Stephen Keenan; Ilias Lavidas; Fergal J Martin; Thomas Maurel; William McLaren; Daniel N Murphy; Rishi Nag; Michael Nuhn; Anne Parker; Mateus Patricio; Miguel Pignatelli; Matthew Rahtz; Harpreet Singh Riat; Daniel Sheppard; Kieron Taylor; Anja Thormann; Alessandro Vullo; Steven P Wilder; Amonida Zadissa; Ewan Birney; Jennifer Harrow; Matthieu Muffato; Emily Perry; Magali Ruffier; Giulietta Spudich; Stephen J Trevanion; Fiona Cunningham; Bronwen L Aken; Daniel R Zerbino; Paul Flicek
Journal:  Nucleic Acids Res       Date:  2015-12-19       Impact factor: 16.971

View more
  12 in total

1.  Epigenetic Regulation of Metabolism and Inflammation by Calorie Restriction.

Authors:  Diego Hernández-Saavedra; Laura Moody; Guanying Bianca Xu; Hong Chen; Yuan-Xiang Pan
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

Review 2.  Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation.

Authors:  Micah G Donovan; Spencer N Wren; Mikia Cenker; Ornella I Selmin; Donato F Romagnolo
Journal:  Br J Pharmacol       Date:  2020-01-26       Impact factor: 8.739

Review 3.  Fasting and cancer: molecular mechanisms and clinical application.

Authors:  Alessio Nencioni; Irene Caffa; Salvatore Cortellino; Valter D Longo
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

4.  Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer.

Authors:  Laura W Bowers; Elaine M Glenny; Arunima Punjala; Nadia A Lanman; Audrey Goldbaum; Caroline Himbert; Stephanie A Montgomery; Peiying Yang; Jatin Roper; Cornelia M Ulrich; Andrew J Dannenberg; Michael F Coleman; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2022-08-01

5.  Reversing the Genomic, Epigenetic, and Triple-Negative Breast Cancer-Enhancing Effects of Obesity.

Authors:  Laura W Bowers; Steven S Doerstling; Meghana G Shamsunder; Claire G Lineberger; Emily L Rossi; Stephanie A Montgomery; Michael F Coleman; Weida Gong; Joel S Parker; Anthony Howell; Michelle Harvie; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2022-09-01

6.  Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.

Authors:  Laura W Bowers; Emily L Rossi; Shannon B McDonell; Steven S Doerstling; Subreen A Khatib; Claire G Lineberger; Jody E Albright; Xiaohu Tang; Linda A deGraffenried; Stephen D Hursting
Journal:  Mol Cancer Res       Date:  2018-02-16       Impact factor: 5.852

7.  Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues.

Authors:  Zhikun Ma; Amanda B Parris; Erin W Howard; Yujie Shi; Shihe Yang; Yunbo Jiang; Lingfei Kong; Xiaohe Yang
Journal:  Carcinogenesis       Date:  2018-10-08       Impact factor: 4.944

8.  Epigenetic Regulation by Dietary Restriction: Part II.

Authors:  Gavin Yong-Quan Ng; David Yang-Wei Fann; Dong-Gyu Jo; Christopher G Sobey; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-12

9.  Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.

Authors:  Virginia Lope; Miguel Martín; Adela Castelló; Amparo Ruiz; Ana Mª Casas; José Manuel Baena-Cañada; Silvia Antolín; Manuel Ramos-Vázquez; José Ángel García-Sáenz; Montserrat Muñoz; Ana Lluch; Ana de Juan-Ferré; Carlos Jara; Pedro Sánchez-Rovira; Antonio Antón; José Ignacio Chacón; Angels Arcusa; Mª Angeles Jimeno; Susana Bezares; Jesús Vioque; Eva Carrasco; Beatriz Pérez-Gómez; Marina Pollán
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

10.  The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth.

Authors:  Laura W Bowers; Claire G Lineberger; Nikki A Ford; Emily L Rossi; Arunima Punjala; Kristina K Camp; Bruce K Kimler; Carol J Fabian; Stephen D Hursting
Journal:  Breast Cancer Res Treat       Date:  2018-10-26       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.